EA015671B1 - Производные бензофуранила как ингибиторы 5-нт6-рецептора - Google Patents

Производные бензофуранила как ингибиторы 5-нт6-рецептора Download PDF

Info

Publication number
EA015671B1
EA015671B1 EA200800071A EA200800071A EA015671B1 EA 015671 B1 EA015671 B1 EA 015671B1 EA 200800071 A EA200800071 A EA 200800071A EA 200800071 A EA200800071 A EA 200800071A EA 015671 B1 EA015671 B1 EA 015671B1
Authority
EA
Eurasian Patent Office
Prior art keywords
compound
body weight
receptor
compounds
obesity
Prior art date
Application number
EA200800071A
Other languages
English (en)
Russian (ru)
Other versions
EA200800071A1 (ru
Inventor
Патриция Кальдирола
Гари Йоханссон
Лори Сутин
Original Assignee
Биовитрум Аб (Пабл)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Биовитрум Аб (Пабл) filed Critical Биовитрум Аб (Пабл)
Publication of EA200800071A1 publication Critical patent/EA200800071A1/ru
Publication of EA015671B1 publication Critical patent/EA015671B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EA200800071A 2005-06-17 2006-06-15 Производные бензофуранила как ингибиторы 5-нт6-рецептора EA015671B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0501383 2005-06-17
US70652305P 2005-08-09 2005-08-09
PCT/EP2006/063249 WO2006134150A1 (en) 2005-06-17 2006-06-15 Benzofuranyl derivatives as 5-ht6-receptor inhibitors

Publications (2)

Publication Number Publication Date
EA200800071A1 EA200800071A1 (ru) 2008-10-30
EA015671B1 true EA015671B1 (ru) 2011-10-31

Family

ID=36659956

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200800071A EA015671B1 (ru) 2005-06-17 2006-06-15 Производные бензофуранила как ингибиторы 5-нт6-рецептора

Country Status (18)

Country Link
US (1) US7582767B2 (cg-RX-API-DMAC7.html)
EP (1) EP1896460B1 (cg-RX-API-DMAC7.html)
JP (1) JP2008543813A (cg-RX-API-DMAC7.html)
KR (1) KR20080017482A (cg-RX-API-DMAC7.html)
CN (1) CN101193885B (cg-RX-API-DMAC7.html)
AU (1) AU2006259082B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0612746A2 (cg-RX-API-DMAC7.html)
CA (1) CA2610383A1 (cg-RX-API-DMAC7.html)
DE (1) DE602006008002D1 (cg-RX-API-DMAC7.html)
DK (1) DK1896460T3 (cg-RX-API-DMAC7.html)
EA (1) EA015671B1 (cg-RX-API-DMAC7.html)
ES (1) ES2330145T3 (cg-RX-API-DMAC7.html)
IL (1) IL187575A (cg-RX-API-DMAC7.html)
MX (1) MX2007015988A (cg-RX-API-DMAC7.html)
NO (1) NO20080354L (cg-RX-API-DMAC7.html)
NZ (1) NZ563510A (cg-RX-API-DMAC7.html)
WO (1) WO2006134150A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200710468B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0303480D0 (sv) * 2003-12-19 2003-12-19 Biovitrum Ab Benzofuranes
WO2014013014A1 (en) 2012-07-18 2014-01-23 Fundació Privada Centre De Regulació Genòmica (Crg) Jak inhibitors for activation of epidermal stem cell populations
CN103880797B (zh) * 2014-03-26 2015-12-02 沈阳大学 苯并呋喃类化合物及其医药用途
WO2018041989A1 (en) 2016-09-02 2018-03-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating refractory celiac disease type 2
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
EP3947737A2 (en) 2019-04-02 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
US20220202820A1 (en) 2019-04-16 2022-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels
EP4526469A1 (en) 2022-05-16 2025-03-26 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002100822A1 (en) * 2001-06-11 2002-12-19 Biovitrum Ab Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes
WO2004000828A1 (en) * 2002-06-20 2003-12-31 Biovitrum Ab New compounds useful for the treatment of obesity, type ii diabetes and cns disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
ATE319683T1 (de) 1998-12-11 2006-03-15 Univ Virginia Commonwealth Selektive 5-ht 6-rezeptor-liganden
RS44204A (sr) * 2001-11-22 2007-06-04 Biovitrum Ab., Inhibitori 11-beta- hidroksistereoidne dehidrogenaze tipa 1
US7943639B2 (en) * 2002-06-20 2011-05-17 Proximagen Limited Compounds
SE0303480D0 (sv) * 2003-12-19 2003-12-19 Biovitrum Ab Benzofuranes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002100822A1 (en) * 2001-06-11 2002-12-19 Biovitrum Ab Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes
WO2004000828A1 (en) * 2002-06-20 2003-12-31 Biovitrum Ab New compounds useful for the treatment of obesity, type ii diabetes and cns disorders

Also Published As

Publication number Publication date
ZA200710468B (en) 2009-04-29
CN101193885B (zh) 2011-07-27
BRPI0612746A2 (pt) 2010-11-30
NZ563510A (en) 2011-01-28
NO20080354L (no) 2008-01-17
US7582767B2 (en) 2009-09-01
IL187575A0 (en) 2008-03-20
JP2008543813A (ja) 2008-12-04
US20060293361A1 (en) 2006-12-28
HK1112918A1 (en) 2008-09-19
AU2006259082A1 (en) 2006-12-21
EP1896460A1 (en) 2008-03-12
KR20080017482A (ko) 2008-02-26
CA2610383A1 (en) 2006-12-21
MX2007015988A (es) 2008-03-07
EP1896460B1 (en) 2009-07-22
IL187575A (en) 2012-12-31
CN101193885A (zh) 2008-06-04
ES2330145T3 (es) 2009-12-04
WO2006134150A1 (en) 2006-12-21
AU2006259082B2 (en) 2011-07-14
DK1896460T3 (da) 2009-11-16
EA200800071A1 (ru) 2008-10-30
DE602006008002D1 (de) 2009-09-03

Similar Documents

Publication Publication Date Title
US20060148818A1 (en) Novel tetraydrospiro(piperdine-2,7'- pyrrolo{3,2-b}pyridine derivatives and novel in-dole derivatives useful in the treatment of 5-ht6 receptor-related disorders
JP2008519083A (ja) アミノキナゾリン化合物
JP2009514954A (ja) Ｔｒｐｖ３機能を変調するための化合物
KR20070097590A (ko) 치환된 아릴아민 화합물 및 5―ｈｔ6 조절제로서의 이의용도
US7566728B2 (en) Remedy for sleep disturbance
JP2002512957A (ja) Ｃｃｒ−３受容体アンタゴニスト
CN1231176A (zh) 治疗心力衰竭的方法
JP2001516718A (ja) ５−ＨＴ再取り込み阻害剤およびｈ５−ＨＴ１Ｂアンタゴニストまたは部分的アゴニストの組み合わせ
EA015671B1 (ru) Производные бензофуранила как ингибиторы 5-нт6-рецептора
JPH01197469A (ja) ピペリジニル化合物類
CN102307861B (zh) 苯基咪唑化合物
CN1094758C (zh) 钙通道的调整
TWI391132B (zh) 憂鬱症或焦慮症用預防或治療劑
JPH02138214A (ja) 不安を治療する方法
JP4166433B2 (ja) ホルモン依存性疾患治療剤
JPWO1999012540A1 (ja) ホルモン依存性疾患治療剤
EA023460B1 (ru) СОЕДИНЕНИЯ (ТИЕНО[2,3-b][1,5]БЕНЗОКСАЗЕПИН-4-ИЛ)ПИПЕРАЗИН-1-ИЛА В КАЧЕСТВЕ СОЕДИНЕНИЙ, ОБЛАДАЮЩИХ ДВОЙНОЙ АКТИВНОСТЬЮ ОБРАТНЫХ АГОНИСТОВ H1/АНТАГОНИСТОВ 5-HT
KR20220152535A (ko) 신규 3,5-디아미노벤조산계 화합물, 및 이것을 사용한 Pin1 저해제 및 염증성 질환의 치료제
CN112209917B (zh) 杂环取代苯基哌嗪或苯基哌啶类衍生物在抗抑郁药物中的应用
EA022708B1 (ru) ЗАМЕЩЕННЫЕ СОЕДИНЕНИЯ [(5H-ПИРРОЛО[2,1-c][1,4]БЕНЗОДИАЗЕПИН-11-ИЛ)ПИПЕРАЗИН-1-ИЛ]-2,2-ДИМЕТИЛПРОПАНОВОЙ КИСЛОТЫ В КАЧЕСТВЕ ОБРАТНЫХ АГОНИСТОВ H1/АНТАГОНИСТОВ 5-HTДВОЙНОГО ДЕЙСТВИЯ
JP2003519229A (ja) 新規ヘテロアリール誘導体、その製造方法及びその使用方法
JP2002255808A (ja) リピド・リッチ・プラーク退縮剤
JPH03261783A (ja) １，２，４―トリアジンジオン化合物及びそれを有効成分とする抗コクシジウム剤
JP2002241267A (ja) 水溶解性が改善された医薬組成物
CN110498789B (zh) 芳烷哌啶类衍生物及其在多靶点抗抑郁症中的应用

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU